چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Vascular disrupting agents (VDAs), a group of cancer remedies, can cause a specific and irreversible destruction of established tumor vessels, and the complete halt of blood flow in the tumor. DMXAA(ASA404) or Vadimezan, a flavone -acetic acid -based drug is the most promising VDAs that induces a rapid shutdown of blood flow in tumor s but not in normal tissue. The exact mechanism of vascular disruption is unknown; however proposed direct and indirect mechanisms of action for DMXAA comprises : i) inducing apoptosis in endothelial cells ; ii) hemorrhagic necrosis and ischemia in tumor ; iii) release of serotonin (5 -HT) ; vi) stimulation of innate immune system ; v) production of inflammatory cytokines e.g. TNF, IL - 6, GCSF , KC, IP -10 , and MCP - 1 ; vi) activation of NFκB and p38 (MAPK); vii) production of nitric oxide and viii) reducing tumor energetics and membrane turnover. Despite the remarkable results from preclinical and Phase I/II, DMXAA ha s failed in phase III clinical trials. The reason for this surprising discrepancy , among others , was discovered to be STING receptor variations between mice and humans. In this review, the development , the mechanism s of DMXAA action , the clinical trials, the combination therapy , and the future of this drug will be discussed. |
| نویسنده | نفر چندم مقاله |
|---|---|
| رعنا جهانبان اسفهلان | دوم |
| خالد صیدی | سوم |
| نصرت اله ضرغامی | پنجم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| An overview on Vadimezan (DMXAA), the vascular disrupting agent.pdf | 1397/04/28 | 502605 | دانلود |
